echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > UCB buys Engage for $270 million, and Staccato Alprazolam, an emergency drug for oral inhalation epilepsy

    UCB buys Engage for $270 million, and Staccato Alprazolam, an emergency drug for oral inhalation epilepsy

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Belgian pharmaceutical company UCB will buy Us company Engage Therapeutics and its epilepsy drug Staccato Alprazolam for $270 millionAccording to the UCB, Staccato Alprazolam is a small hand-held oral inhalation epilepsy emergency therapy that could become the first on-demand, one-in-one inhalation, by rapidly atomizing high doses of apurquinon and delivering the drug to the lungs, which can quickly end active seizures", and may be used in all 30 to 30 percent of epilepsy patientsStaccato Inhalers (Photo: Engage Therapeutics) It takes 15 minutes for the two epileptic spray therapies currently on the market to work, meaning it's not enough to stop the seizures that have already startedThe StATES results, a Phase 2b trial reported by Engage earlier this year, showed that 66% of patients who received the drug as an active first aid treatment controlled symptoms within two minutes and did not relapse within two hoursOnly 43 percent of patients in the placebo group achieved this effect, suggesting that the differencebetween between the two groups was statistically significant, the data were presented in April at the virtual American Congress of NeurologyStaccato inhalers have entered the U.Sand European markets as an integral part of Alexza Adasupin for acute treatment of agitation associated with adult schizophrenia or bipolar disorder
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.